Immunoproteasome subunits are novel signatures for predicting efficacy of immunotherapy in muscle invasive bladder cancer.

J Transl Med · 2025 · PMC11863778 · PMID 40012053

Europe PMC DOI

hedged sentences

0.0850

closest p · 1.7× alpha

0.2960

boldest claim

The sentences

an obvious trendP = 0.085so close (0.05 < p ≤ 0.1)

25.0 months; HR, 0.52; 95% CI, 0.28–0.97; P = 0.041) and an obvious trend of a prolonged OS (median, 38.0 vs. 31.0 months; HR, 0.55; 95% CI, 0.28–1.08; P = 0.085) compared with the PSMB9 low MIBC population in the CQUCH cohort (Fig. 2 A).

also in 250 other papers

did not reach statistical significanceP = 0.296not close (p > 0.1)

Although PFS and OS values of the PSMB8 high MIBC population indicated an improved survival in response to immunotherapy compared with the PSMB8 low MIBC population, data did not reach statistical significance (mPFS, 33.0 vs. 15.0 months; P = 0.296; mOS, 33.0 vs. 20.0 months; P = 0.304) (Fig. 3 B).

also in 28,709 other papers

showed a trendno p-value reported

MIBC patients with high expression of immunoproteasome subunits, especially high expression of PSMB9, showed a trend of prolonged overall and progression free survival, which was further significantly improved in response to immunotherapy.

also in 15,197 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.